MR Elastography of Cognitive Impairment

NCT ID: NCT06029114

Last Updated: 2024-12-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

450 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-11

Study Completion Date

2027-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research is to further investigate the potential of brain stiffness as a novel biomarker for Alzheimer's disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Due to shifting demographics, the prevalence of dementia continues to increase in the population. To mitigate the effects of dementia will require new treatments working jointly with new methods for earlier and more sensitive diagnosis of the diseases. Magnetic resonance elastography (MRE) is a noninvasive technique for measuring tissue stiffness. MRE is a three-step process beginning with the introduction of shear waves into the tissue of interest with an external vibration source. The shear waves are imaged with a phase-contrast MRI pulse sequence and the resulting wave images are mathematically inverted to calculate tissue stiffness.

Preliminary data indicate that global brain stiffness is highly reproducible and that Alzheimer's disease causes a decrease in brain stiffness when compared to age- and gender-matched cognitively normal controls. The purpose of the proposed work is to further investigate the potential of brain stiffness as a novel biomarker for Alzheimer's disease. A comparison between brain stiffness and existing Alzheimer's disease biomarkers will help determine the biological basis of the observed stiffness change and in time may improve the sensitivity of Alzheimer's disease diagnosis and grading.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease Mild Cognitive Impairment Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy Control Group

Subjects will have a magnetic resonance elastography (MRE) performed.

Magnetic Resonance Elastography (MRE)

Intervention Type DIAGNOSTIC_TEST

Imaging technique performed on a Compact 3T MRI scanner that measures the stiffness (mechanical properties) of tissues.

Alzheimer's Disease Group

Subjects will have a magnetic resonance elastography (MRE) performed.

Magnetic Resonance Elastography (MRE)

Intervention Type DIAGNOSTIC_TEST

Imaging technique performed on a Compact 3T MRI scanner that measures the stiffness (mechanical properties) of tissues.

Mild Cognitive Impairment Group

Subjects will have a magnetic resonance elastography (MRE) performed.

Magnetic Resonance Elastography (MRE)

Intervention Type DIAGNOSTIC_TEST

Imaging technique performed on a Compact 3T MRI scanner that measures the stiffness (mechanical properties) of tissues.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Magnetic Resonance Elastography (MRE)

Imaging technique performed on a Compact 3T MRI scanner that measures the stiffness (mechanical properties) of tissues.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* In good general health
* No Active neurological or psychiatric conditions, if a prior neurological or psychiatric condition was present they must have returned to normal
* No cognitive complaints
* Normal neurological examination
* No psychoactive medications
* They may have a chronic medical condition that does not affect cognition
* Low Aβ load Pittsburgh compound-B (PiB) ratio \<1.5


* In good general health
* Memory complaint documented by the patient and collateral source
* Normal general cognitive function as determined by measure of general intellectual function and screening including the Short Test of Mental Status
* Normal activities of daily living as documented by history and Record of Independent Living
* Not demented by DSM-III-R criteria
* Do have an objective memory impairment determined by the clinical judgement of the neuropsychologists and neurologists
* High Aβ load Pittsburgh compound-B (PiB) ratio ≥1.5


* In good general health
* Dementia not a result of other medical or psychiatric conditions
* Diagnosis of dementia made according to DSM-III-R criteria
* Do have objective memory impairment determined by the clinical judgement of the neuropsychologists and neurologists
* High Aβ load Pittsburgh compound-B (PiB) ratio ≥1.5

Exclusion Criteria

* Alzheimer's disease or mild cognitive impairment due to a known genetic mutation
* Major depression
* History of primary or metastatic intracranial neoplasm, significant head trauma, intra-cerebral hemorrhage, hemispheric stroke
* Contradictions to MRI imaging including but not limited to cardiac pacemakers, intraocular or intracranial metal, or other MRI incompatible devices.
* Pregnant women. Women of child bearing potential will be given a urine pregnancy test prior the MRI scan. Results will be shared with the participant. If the pregnancy test is positive, the participant will not be included within the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute on Aging (NIA)

NIH

Sponsor Role collaborator

Mayo Clinic

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

John Huston

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

John Huston, MD

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mayo Clinic Minnesota

Rochester, Minnesota, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R01AG076636

Identifier Type: NIH

Identifier Source: secondary_id

View Link

23-004125

Identifier Type: -

Identifier Source: org_study_id